(Q46187419)

20 December 2017

title

The impact of mTOR inhibitors on the development of malignancy (English)

1 reference

20 December 2017

author name string

E K Geissler

series ordinal

1

1 reference

20 December 2017

language of work or name

English

0 references

publication date

1 December 2008

1 reference

20 December 2017

Transplantation Proceedings

published in

1 reference

20 December 2017

volume

40

1 reference

20 December 2017

issue

10 Suppl

1 reference

20 December 2017

page(s)

S32-5

1 reference

20 December 2017

Identifying High Risk Groups and Quantifying Absolute Risk of Cancer After Kidney Transplantation: A Cohort Study of 15 183 Recipients

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Antiangiogenesis drug promising for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Development of de novo cancer in p53 knock-out mice is dependent on the type of long-term immunosuppression used

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Peritoneal leiomyosarcoma in a kidney transplant patient: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.10.017

10.1016/J.TRANSPROCEED.2008.10.017

7 January 2021

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017